Estrogen receptor mutations and their role in breast cancer progression

Prasanna G. Alluri, Corey Speers, Arul M. Chinnaiyan

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Endocrine therapy is the mainstay of treatment in estrogen receptor-positive breast cancers and significantly reduces disease recurrence and breast cancer-related mortality. However, acquired resistance to therapy has been noted in nearly one-third of women treated with tamoxifen and other endocrine therapies. Mutations in the estrogen receptor have long been speculated to play a role in endocrine therapy resistance but have been rarely detected. However, recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic clinical samples have revealed that recurrent ESR1 mutations are far more frequent than previously thought and may play an important role in acquired endocrine therapy resistance. Here we review recent advances in detection and characterization of ESR1 mutations in advanced, endocrine therapy-resistant breast cancers.

Original languageEnglish (US)
Number of pages1
JournalBreast cancer research : BCR
Volume16
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Estrogen Receptors
Breast Neoplasms
Mutation
Therapeutics
Tamoxifen
Recurrence
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Estrogen receptor mutations and their role in breast cancer progression. / Alluri, Prasanna G.; Speers, Corey; Chinnaiyan, Arul M.

In: Breast cancer research : BCR, Vol. 16, No. 6, 01.01.2014.

Research output: Contribution to journalReview article

@article{4ce9fdbcbe734cd4a4f4436825d8e95c,
title = "Estrogen receptor mutations and their role in breast cancer progression",
abstract = "Endocrine therapy is the mainstay of treatment in estrogen receptor-positive breast cancers and significantly reduces disease recurrence and breast cancer-related mortality. However, acquired resistance to therapy has been noted in nearly one-third of women treated with tamoxifen and other endocrine therapies. Mutations in the estrogen receptor have long been speculated to play a role in endocrine therapy resistance but have been rarely detected. However, recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic clinical samples have revealed that recurrent ESR1 mutations are far more frequent than previously thought and may play an important role in acquired endocrine therapy resistance. Here we review recent advances in detection and characterization of ESR1 mutations in advanced, endocrine therapy-resistant breast cancers.",
author = "Alluri, {Prasanna G.} and Corey Speers and Chinnaiyan, {Arul M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1186/s13058-014-0494-7",
language = "English (US)",
volume = "16",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Estrogen receptor mutations and their role in breast cancer progression

AU - Alluri, Prasanna G.

AU - Speers, Corey

AU - Chinnaiyan, Arul M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Endocrine therapy is the mainstay of treatment in estrogen receptor-positive breast cancers and significantly reduces disease recurrence and breast cancer-related mortality. However, acquired resistance to therapy has been noted in nearly one-third of women treated with tamoxifen and other endocrine therapies. Mutations in the estrogen receptor have long been speculated to play a role in endocrine therapy resistance but have been rarely detected. However, recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic clinical samples have revealed that recurrent ESR1 mutations are far more frequent than previously thought and may play an important role in acquired endocrine therapy resistance. Here we review recent advances in detection and characterization of ESR1 mutations in advanced, endocrine therapy-resistant breast cancers.

AB - Endocrine therapy is the mainstay of treatment in estrogen receptor-positive breast cancers and significantly reduces disease recurrence and breast cancer-related mortality. However, acquired resistance to therapy has been noted in nearly one-third of women treated with tamoxifen and other endocrine therapies. Mutations in the estrogen receptor have long been speculated to play a role in endocrine therapy resistance but have been rarely detected. However, recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic clinical samples have revealed that recurrent ESR1 mutations are far more frequent than previously thought and may play an important role in acquired endocrine therapy resistance. Here we review recent advances in detection and characterization of ESR1 mutations in advanced, endocrine therapy-resistant breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=84986328209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986328209&partnerID=8YFLogxK

U2 - 10.1186/s13058-014-0494-7

DO - 10.1186/s13058-014-0494-7

M3 - Review article

VL - 16

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 6

ER -